DRIVE2Simplify Exploratory Analysis: Metabolic Outcomes With Islatravir Plus DOR vs DOR/3TC/TDF in ART-Naive Adults at Wk 48

March 8-11, 2020; Boston, Massachusetts
Changes in weight, body fat, BMD, and fasting lipid parameters were comparable among varying doses of islatravir + DOR vs DOR/3TC/TDF at Week 48 in ART-naive patients.
Format: Microsoft PowerPoint (.ppt)
File Size: 215 KB
Released: March 14, 2020

Acknowledgements

Provided by USF Health, in partnership with Clinical Care Options, LLC

USF Health
Office of Continuing Professional Development (OCPD)
124 S. Franklin Street
Tampa, FL 33602

(800) 852-5362
(813) 224-7860
(813) 224-7864 (Fax)
cpdsupport@usf.edu
https://health.usf.edu/cpd

This activity is supported by educational grants from
Gilead Sciences
Merck & Co., Inc.
ViiV Healthcare

Related Content

Expert-authored CCO slides on strategies encompassed by the Ending the HIV Epidemic Initiative, including prevention and rapid diagnosis and treatment

W. David Hardy, MD
Program Director
David A. Wohl, MD
Released: October 20, 2020

Download CCO slides reviewing data and guidelines on management of heavily-treatment experienced patients with HIV experiencing treatment failure

Joseph J. Eron, Jr., MD Princy N. Kumar, MD, FIDSA, MACP Released: October 20, 2020

Expert-authored CCO slides on simplification to 2-drug ART, ART safety during pregnancy, ART and weight gain, and long-acting injectable ART

W. David Hardy, MD
Program Director
Michelle S. Cespedes, MD, MS
Released: October 20, 2020

CCO slides on ending the HIV epidemic in the United States via expanded testing, enhanced linkage to care, and rapid response to potential outbreaks

Lisa K. Fitzpatrick, MD, MPH, MPA David Malebranche, MD, MPH Released: October 7, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue